fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Bicalutamide

All products: general benefit

Apo-Bicalutamide · DIN 02296063 · 50 mg · tablet

General benefitDormant since May 14, 2023 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apo-Bicalutamide · DIN 02296063 Manufacturer: Apotex Inc.; listing date 2008-01-15 Health Canada: Dormant since 2023-05-14 · brand APO-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Bicalutamide: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2690). What the ministry pays, not the patient.

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02296063)

Source record
DIN 02296063: Apo-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296063 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78142
Interchangeable products
Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: discontinued (May 12, 2022, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296063
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 14, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L02B, L02BB): coverage varies; not interchangeable

  • Flutamide (Euflex): general benefit, not a benefit
  • Enzalutamide (Xtandi): not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-BICALUTAMIDE (bicalutamide) 50 mg is indicated for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer. Pediatrics: The safety and effectiveness of bicalutamide in children has not been established. https://pdf.hres.ca/dpd_pm/00041652.PDF PM date: September 27, 2017 Source product: TEVA-BICALUTAMIDE; DIN 02270226; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Bicalutamide · DIN 02296063 Shortage status: discontinued (2022-05-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296063

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)